Increased circulating myeloid-derived suppressor cells in vivax malaria and severe falciparum malaria.
Clinical
MDSC
Malaria
Severe falciparum
Vivax
Journal
Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802
Informations de publication
Date de publication:
06 Sep 2022
06 Sep 2022
Historique:
received:
05
03
2022
accepted:
16
08
2022
entrez:
6
9
2022
pubmed:
7
9
2022
medline:
9
9
2022
Statut:
epublish
Résumé
Circulating myeloid-derived-suppressor-cells (MDSC) with immunosuppressive function are increased in human experimental Plasmodium falciparum infection, but have not been studied in clinical malaria. Using flow-cytometry, circulating polymorphonuclear-MDSC were evaluated in cryopreserved samples from patients with uncomplicated Plasmodium vivax (n = 8) and uncomplicated (n = 4) and severe (n = 16) falciparum malaria from Papua, Indonesia. The absolute number of circulating polymorphonuclear-MDSC were significantly elevated in severe falciparum malaria patients compared to controls (n = 10). Polymorphonuclear-MDSC levels in uncomplicated vivax malaria were also elevated to levels comparable to that seen in severe falciparum malaria. Control of expansion of immunosuppressive MDSC may be important for development of effective immune responses in falciparum and vivax malaria.
Sections du résumé
BACKGROUND
BACKGROUND
Circulating myeloid-derived-suppressor-cells (MDSC) with immunosuppressive function are increased in human experimental Plasmodium falciparum infection, but have not been studied in clinical malaria.
METHODS
METHODS
Using flow-cytometry, circulating polymorphonuclear-MDSC were evaluated in cryopreserved samples from patients with uncomplicated Plasmodium vivax (n = 8) and uncomplicated (n = 4) and severe (n = 16) falciparum malaria from Papua, Indonesia.
RESULTS
RESULTS
The absolute number of circulating polymorphonuclear-MDSC were significantly elevated in severe falciparum malaria patients compared to controls (n = 10). Polymorphonuclear-MDSC levels in uncomplicated vivax malaria were also elevated to levels comparable to that seen in severe falciparum malaria.
CONCLUSION
CONCLUSIONS
Control of expansion of immunosuppressive MDSC may be important for development of effective immune responses in falciparum and vivax malaria.
Identifiants
pubmed: 36068577
doi: 10.1186/s12936-022-04268-6
pii: 10.1186/s12936-022-04268-6
pmc: PMC9446641
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
255Subventions
Organisme : Wellcome Trust
ID : 200909/Z/16/Z
Pays : United Kingdom
Organisme : National Health and Medical Research Council
ID : 1021198
Organisme : National Health and Medical Research Council
ID : 1037304
Organisme : Wellcome Trust
ID : 091625
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 062058
Pays : United Kingdom
Informations de copyright
© 2022. The Author(s).
Références
Crit Care. 2014 Aug 01;18(4):R163
pubmed: 25084831
Blood. 2009 Dec 24;114(27):5522-31
pubmed: 19837977
Infect Immun. 2015 Aug;83(8):3224-32
pubmed: 26034211
Nat Rev Immunol. 2021 Aug;21(8):485-498
pubmed: 33526920
J Exp Med. 2007 Oct 29;204(11):2693-704
pubmed: 17954570
J Reprod Immunol. 2016 Feb;113:35-41
pubmed: 26599285
PLoS Pathog. 2009 Apr;5(4):e1000402
pubmed: 19390618
Trop Med Int Health. 2014 Sep;19 Suppl 1:7-131
pubmed: 25214480
Ann Surg. 2017 Apr;265(4):827-834
pubmed: 27163951
Infect Immun. 2017 May 23;85(6):
pubmed: 28320838
PLoS One. 2015 Apr 17;10(4):e0124080
pubmed: 25884830
J Leukoc Biol. 2013 Apr;93(4):633-7
pubmed: 23341539
Cell Death Dis. 2020 Oct 27;11(10):921
pubmed: 33110074
Cell Death Dis. 2017 Mar 23;8(3):e2695
pubmed: 28333137
J Infect Dis. 2019 May 24;219(12):1994-2004
pubmed: 30452670
Nat Immunol. 2010 Jun;11(6):477-85
pubmed: 20431620
PLoS One. 2016 Oct 27;11(10):e0165340
pubmed: 27788243
Infect Immun. 2022 Feb 17;90(2):e0043521
pubmed: 34871039
PLoS Med. 2020 Oct 19;17(10):e1003359
pubmed: 33075101
J Leukoc Biol. 2017 May;101(5):1091-1101
pubmed: 28007981
Cell Death Differ. 2020 Nov;27(11):3196-3207
pubmed: 32514047
PLoS One. 2012;7(2):e31524
pubmed: 22348096
Malar J. 2008 Aug 02;7:148
pubmed: 18673572
Eur J Immunol. 2010 Nov;40(11):2976-85
pubmed: 21061431
Front Immunol. 2021 Mar 19;12:625712
pubmed: 33815377
Sci Immunol. 2016 Aug;1(2):
pubmed: 28417112
Oncoimmunology. 2017 Jan 9;6(2):e1258504
pubmed: 28344866